Suppr超能文献

依维莫司联合吉西他滨对弥漫性大B细胞淋巴瘤的协同抗肿瘤作用

[Synergistic Antitumor Effect of Everolimus Combined with Gemcitabine on Diffuse Large B-Cell Lymphoma].

作者信息

Zuo Xiu-Qin, Tan Chun-Lian, Li Xiao-Ming, Ma Tao

机构信息

Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.

Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou 646000, Sichuan Province, China.E-mail:

出版信息

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2023 Feb;31(1):81-88. doi: 10.19746/j.cnki.issn.1009-2137.2023.01.013.

Abstract

OBJECTIVE

To investigate the effects of mTOR inhibitors everolimus (EVE) and gemcitabine (GEM) on the proliferation, apoptosis and cell cycle of diffuse large B-cell lymphoma (DLBCL) cell line U2932, and further explore the molecular mechanisms, so as to provide new ideas and experimental basis for the clinical treatment of DLBCL.

METHODS

The effect of EVE and GEM on the proliferation of U2932 cells was detected by CCK-8 assay, the IC of the two drugs was calculated, and the combination index (=) of the two drugs was calculated by CompuSyn software. The effect of EVE and GEM on apoptosis of U2932 cells was detected by flow cytometry with AnnexinV-FITC/PI staining. Flow cytometry with propidium iodide (PI) staining was used to detect the effect of EVE and GEM on the cell cycle of U2932 cells. Western blot assay was used to detect the effects of EVE and GEM on the channel proteins p-mTOR and p-4EBP1, the anti-apoptotic proteins MCL-1 and Survivin, and the cell cycle protein Cyclin D1.

RESULTS

Both EVE and GEM could significantly inhitbit the proliferation of U2932 cells in a time- and dose-dependent manner (=0.465, 0.848; 0.555, 0.796). According to the calculation of CompuSyn software, EVE combined with GEM inhibited the proliferation of U2932 cells at 24, 48 and 72 h with =<1, which had a synergistic effect. After treated U2932 cells with 10 nmol/L EVE, 250 nmol/L GEM alone and in combination for 48 h, both EVE and GEM induced apoptosis, and the difference was statistically significant compared with the control group (<0.05). The apoptosis rate was significantly enhanced after EVE in combination with GEM compared with single-agent (<0.05). Both EVE and GEM alone and in combination significantly increased the proportion of cells in G phase compared with the control group (<0.05). The proportion of cells in G phase was significantly increased when the two drugs were combined (<0.05). The expression of p-mTOR and effector protein p-4EBP1 was significantly downregulated in the EVE combined with GEM group, the expression of anti-apoptotic proteins MCL-1, Survivin and cell cycle protein cyclin D1 was downregulated too (<0.05).

CONCLUSION

EVE combined with GEM can synergistically inhibit the proliferation of U2932 cells, and the mechanism may be that they can synergistically induce apoptosis by downregulating the expression of MCL-1 and Survivin proteins and block the cell cycle progression by downregulating the expression of Cyclin D1.

摘要

目的

探讨mTOR抑制剂依维莫司(EVE)与吉西他滨(GEM)对弥漫性大B细胞淋巴瘤(DLBCL)细胞系U2932增殖、凋亡及细胞周期的影响,并进一步探究其分子机制,为DLBCL的临床治疗提供新思路和实验依据。

方法

采用CCK-8法检测EVE和GEM对U2932细胞增殖的影响,计算两种药物的半数抑制浓度(IC),并通过CompuSyn软件计算两种药物的联合指数(CI)。采用AnnexinV-FITC/PI染色,通过流式细胞术检测EVE和GEM对U2932细胞凋亡的影响。采用碘化丙啶(PI)染色,通过流式细胞术检测EVE和GEM对U2932细胞周期的影响。采用蛋白质免疫印迹法检测EVE和GEM对通路蛋白p-mTOR和p-4EBP1、抗凋亡蛋白MCL-1和Survivin以及细胞周期蛋白Cyclin D1的影响。

结果

EVE和GEM均能以时间和剂量依赖性方式显著抑制U2932细胞的增殖(CI=0.465,0.848;0.555,0.796)。根据CompuSyn软件计算,EVE与GEM联合使用在24、48和72 h时抑制U2932细胞增殖的CI<1,具有协同作用。用10 nmol/L EVE、250 nmol/L GEM单独及联合处理U29

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验